BCG vaccination in southern rural Mozambique: an overview of
                coverage and its determinants based on data from the demographic
                and health surveillance system in the district of Manhica by Marbán Castro, Elena et al.
RESEARCH ARTICLE Open Access
BCG vaccination in southern rural
Mozambique: an overview of coverage and
its determinants based on data from the
demographic and health surveillance
system in the district of Manhiça
Elena Marbán-Castro1, Charfudin Sacoor2, Ariel Nhacolo2, Orvalho Augusto2, Edgar Jamisse2, Elisa López-Varela1,2,
Aina Casellas1, John J. Aponte1,2, Quique Bassat1,2,3, Betuel Sigauque2, Eusebio Macete2
and Alberto L. Garcia-Basteiro1,2,4*
Abstract
Background: Over the past four decades, the World Health Organization established the Expanded Programme on
Immunization (EPI) to foster universal access to all relevant vaccines for all children at risk. The success of this
program has been undeniable, but requires periodic monitoring to ensure that coverage rates remain high.
The aim of this study was to measure the BCG vaccination coverage in Manhiça district, a high TB burden
rural area of Southern Mozambique and to investigate factors that may be associated with BCG vaccination.
Methods: We used data from the Health and Demographic Surveillance System (HDSS) run by the Manhiça
Health Research Centre (CISM) in the district of Manhiça. A questionnaire was added in the annual HDSS round visits to
retrospectively collect the vaccination history of children under the age of 3 years. Vaccinations are registered in the
National Health Cards which are universally distributed at birth. This information was collected for children born from
2011 to 2014. Data on whether a child was vaccinated for BCG were collected from these National Health Cards and/or
BCG scar assessment.
Results: A total of 10,875 number of children were eligible for the study and 7903 presented the health card.
BCG coverage was 97.4% for children holding a health card. A BCG-compatible scar was observed in 99.0% of
all children and in 99.6% of children with recorded BCG in the card. A total of 93.4% of children had been
vaccinated with BCG within their first 28 days of life. None of the factors analysed were found to be associated with lack
of BCG vaccination except for living in the municipality of Maluana compared to living in the municipality of Manhiça;
(OR = 1.89, 95% CI: 1.18-3.00). Coverage for other EPI vaccines during the first year of life was similarly high, but
decreased for subsequent doses.
Conclusions: BCG coverage is high and timely administered. Almost all vaccinated infants develop scar, which is a
useful proxy for monitoring BCG vaccine implementation.
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Background
Tuberculosis (TB) remains a global public health con-
cern, responsible for an estimated 1.8 million deaths in
2015. It stands as the leading cause of death by an infec-
tious agent worldwide [1]. The only available vaccine to
fight TB is the Bacille Calmette-Guérin (BCG) vaccine,
first administered in 1921 and, probably the most widely
used vaccine in the world [2, 3]. Although the efficacy of
BCG against pulmonary TB has been questioned [4], it
remains an essential approach for prevention of the
most severe forms of TB in children (with an estimated
efficacy against miliary TB and TB meningitis of 77 and
73% respectively) [5, 6]. It also reduces infection [7] and
all-cause mortality through non-specific effects of the
immune system [8]. A recent study has shown a long-
lasting protection of BCG, being more cost-effective
than previously thought [9]. Moreover, non TB beneficial
effects have been reported such as protection against
other causes of death, or reduced risk of death from
pneumonia and malaria (studies from African and Asian
low-income countries) [2, 10, 11]. Administered at birth,
BCG reduces neonatal mortality by 48% in low-birth
weight infants [12]. An added importance of BCG is its
proximity to the delivery event and thus being the entry
point to EPI and other health packages [12].
The WHO recommends vaccinating all newborns in
endemic areas with BCG at birth, except in cases of
positive or suspicion of HIV infection [4]. In settings
where HIV status cannot be discarded at the time of vac-
cination, for example, infants born to HIV-positive
mothers with unknown status and lacking suggestive
symptoms, BCG should be given after considering local
epidemiology.
The development of a scar secondary to BCG
vaccination is a good indicator of vaccination re-
sponse, associated with reduction of childhood mor-
tality [5, 11, 13], but there are other factors involved
in the lack of the immune response, such as cold
chain management. The most widely used strategies
to assess BCG vaccination include the verification of
its administration through vaccination cards [2, 14–
19] and the direct observation of a BCG-compatible
scar [2, 14, 20, 21]. Studies have reported many risk
factors associated with no vaccination, including fe-
male gender, great number of siblings, lower
mother’s education, low knowledge of vaccine sched-
ule, single or divorced marital status, poor wealth
index and low density of health workers, among
others [14, 17, 21–24].
Mozambique is one of the countries with highest TB
incidence and lowest TB case detection rates in the
world [1, 25]. A recent study showed that TB is associ-
ated with 6.5% of all deaths in a rural district in the
south of the country [26]. TB control strategies are
based on improving and enhancing access to diagnosis
treatment, and prevention through vaccination or pre-
ventive treatment. The Mozambican Expanded
Programme on Immunization (EPI) was first introduced
in 1979 with a commitment of reducing infant mortality
and morbidity by immunization [27]. Nevertheless, con-
straints related to its weak performance have been iden-
tified at several levels: poor programme data
management, inadequate logistic, insufficient financial
resources and cold chain management, among others
[27]. A complete immunization program for the first
year of life includes BCG and an Oral Polio Vaccine
(OPV) at birth, three more doses of OPV and three
doses of pentavalent vaccine (Diphtheria, Tetanus, Per-
tussis, Hepatitis B, Haemophilus influenzae type b) at 6,
10 and 14 weeks, and a measles vaccine at month 9 re-
spectively. More recently, the conjugate vaccines against
pneumococcal disease (2009) and against rotavirus
(2011) have also been added to this schedule. Vaccines
are administered free of charge and at several peripheral
health care centres, widening the possibilities of being
vaccinated.
The WHO (2015) reports an official estimated BCG
coverage for Mozambique of 95% based on data from
the Demographic and Health Survey [28]. However, the
reliability of these official estimates has been questioned
because BCG vaccination coverage differs from institu-
tion to institution and estimates have been reported
above 100% [18, 29]. Moreover, critical BCG vaccine
shortages have been reported between 2013 to 2015 in
many countries [30]. Thus, this study was conducted to
measure BCG vaccination coverage among children
below 36 months of age, through BCG recorded in na-
tional health cards and by BCG scar assessment. As sec-
ondary objectives, we aimed to a) analyse BCG
timeliness, in order to evaluate whether the vaccine was
given in the right time period b) compare the coverage of
BCG to other vaccines and c) identify the socio-
demographic factors that might be associated with lack
of BCG vaccination.
Methods
Study design and setting
The study was conducted in the district of Manhiça,
Maputo Province, a rural area of Southern Mozambique,
where the Manhiça Health Research Centre (CISM) runs
a Health and Demographic Surveillance System (HDSS)
since its foundation in 1996 [31]. It is a high TB and
HIV burden area [32, 33]. In 2014, the HDSS was ex-
panded to cover the entire district, an area of 2380 km2
that comprises around 38,000 enumerated and geo-
positioned households, and about 178,000 individuals.
Compared to the official census, DHS, health service
data and civil registrations, the HDSS is considered
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a gold standard tool for population indicators and cross-
national comparisons [1, 34].
In Mozambique, where high pediatric TB rates and
low case detection rates have been reported [35, 36],
children receive a national health card (also called
“vaccination card”) at birth or in their first contact
with the health system, where immunization, an-
thropometric and basic health data are registered. All
children born in the district of Manhiça participate in
the HDSS.
Design / participants
In every HDSS round, demographic information about
births, deaths and migration is updated. This is a
cross-sectional study performed at the time of the
HDSS census rounds of 2014 and 2015, which in-
cluded a specific form to collect information about
vaccination status. In each round, information was
collected for children who were up to 3 years of age,
thus in the round of 2014, children born in 2011,
2012 and 2013 were evaluated; and from 2012 on-
wards for the round of 2015. Information for all chil-
dren who were less than 36 months of age at the
HDSS census rounds was selected. Health cards,
whenever available, were evaluated by the field
worker, who collected information about administra-
tion of all vaccines. In order to estimate BCG and
other EPI vaccines coverage through the assessment
of vaccination card, we only included children who
presented the card at the time of the interview; in
order to assess BCG vaccination coverage through the
presence of scar, we included all children observed at
the visits.
Data collection and analysis
Data cleaning, prior to data analysis, included deletion
of duplicated records or incomplete variables. Dupli-
cated observations occurred because the questionnaire
was administered to every child irrespective of having
or not responded to previous rounds. This allowed to
have the most updated information for missed
children in previous visits and newborns. When du-
plicate observations were present, those observations
with the most complete data for all variables were
preserved.
BCG vaccination coverage (VC) was defined as the
proportion of children with recorded BCG vaccine in
their health card divided among children whose health
card was assessed and readable. VC was calculated as a
proportion of children receiving a BCG or other EPI
vaccines divided by the total number of eligible children
(those who should have received it according to their
age at the time of the visit and whose health card was
assessed, readable and without missing dates). VC was
calculated as a proportion, with 95% confidence intervals
(CI). Information about children included variables such
as sex, number of siblings, season of birth and area of
residence. Mothers’ data was obtained from other HDSS
questionnaires in which information about family mem-
bers is routinely collected, including religion, education
or marital status. Variables at household level, such as
wealth index and distance to nearest health centre were
also included. The variable wealth index was estimated
using principal component analysis (PCA) with variables
related to the household assets following the recommen-
dations of Vyas et al. [37].
To measure the coverage of BCG through scar assess-
ment, the number of children who presented a BCG scar
was divided by the total number of children assessed for
scarring. The coverage was also measured among chil-
dren with and without health cards and among children
with BCG according to their health card. Delay in BCG
administration was defined as a child receiving BCG vac-
cine after the first 28 days of life.
In the descriptive analysis absolute and relative fre-
quencies were calculated. The description included
qualitative variables and quantitative variables catego-
rized according to the objective of the study.
Every variable which a priori seemed to be poten-
tially associated with absence of BCG vaccination in
the card was tabulated against BCG administration.
Odds Ratios with a 95% CI and p-values were calcu-
lated. A stepwise procedure was carried out in order
to build a multivariate logistic regression model using
those variables with p-values < 0.15 in the univariate
analysis.
The analysis was conducted using Stata 13 (StataCorp
LP, College Station, TX, USA). Graphs and tables were
produced with Excel (Microsoft Office 2016, USA).
Results
Population and socio-demographic characteristics
According to CISM’s HDSS database, 11,537 children
were born between 1st January 2011 and 31st December
2014 in the district of Manhiça. From the 10,875 eligible
children (born in that period and under 36 months at
the time of annual visits), 9512 children were visited.
Around 72.9% (7903/10,875) of children presented a
health card to the field workers for transcription of the
information on vaccination. Of 2972 children whose
card was not available, 48.9% of cases declared the rea-
son was that the adult responding to the HDSS ques-
tions could not find the card and, in almost a quarter,
23.1%, no reason was recorded.
BCG and other vaccines coverage
Among children with a health card, information about
BCG vaccination (either yes or no) was recorded in
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98.9% of the cases and, from those, 91.9% were present
at the time of the interview allowing the evaluation of
their arm to see the scar post BCG vaccination (see
Fig. 1). Regardless of having the vaccination card, 8298
children were evaluated for presence of BCG scar. Char-
acteristics of study participants are described in Table 1.
Additional file 1 presents the characteristics of infants
with and without health card.
A total of 7612 children under the age of 36 months
whose national health card was evaluated were BCG vac-
cinated in the district of Manhiça, yielding a BCG cover-
age of 97.4%. Table 2 and Fig. 2 show the vaccination
coverage for all EPI vaccines administered in the district
of Manhiça in the first year of life during the years 2011
to 2014. Coverage for each of the four doses of Oral
Polio Vaccines were: 96.3%, 95.6%, 93.8% and 92.1%. For
the pentavalent DPT/HepB/Hib vaccine, coverage was
96%, 94.5% and 93%. Measles vaccine was received
around month 9 of life by 85.6% of infants. Around
90.2% of all study children had received all four doses of
Oral Polio Vaccine and 91.8% of the doses of the
pentavalent vaccine DPT/HepB/Hib. We found no
differences in coverage for any of the vaccines by year of
vaccination.
The multivariable logistic regression model revealed
that children born in the municipality of Maluana had
89% higher odds of not receiving the vaccine compared
to those born in central Manhiça (OR = 1.89, 95% CI:
1.18-3.00). Mothers’ marital status (divorced or not liv-
ing with a male companion vs married or living with a
male companion) showed a weak association with lack
of vaccination: OR = 1.66 95% CI: 0.81-3.37) (Table 3).
Fig. 1 Flow of study participants. Children less than 36 months of age born in Manhiça from 2011 to 2014 and eligible to participate in the
study: an adult was at home when interviews occurred, they presented the child’s health card and the children were alive
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No other factors were associated with lack of BCG
vaccination.
Scar assessment
From the 9512 adults who responded to the interview,
irrespective of whether they presented the national
health card or not, 8298 children could be directly ob-
served for the presence of BCG-compatible scar. Cover-
age was 99.0% and 97.9% among children with and
without a health card respectively. Therefore, when chil-
dren are vaccinated with BCG (according to the health
card), failure to develop the typical scar would occur in
less than 1% in this population. We did not find any sta-
tistically significant association with lack of BCG scar.
There were 174 children who were not BCG vaccinated
according to the card, but 144 of them presented a
BCG-compatible scar (82.8%).
Timeliness of BCG
Figure 3 represents the distribution of BCG vaccines ad-
ministered to children starting from the day of birth on-
wards. The results indicate that 93.4% of vaccinated
children received BCG within the first 28 days of life.
The factors associated with the administration of BCG
in the first 28 days of life are described in Table 4. The
only factor associated with a timely BCG administration
is not being born by a cesarean section (for which OR =
0.40, p-value 0.021). In other words, children born
through a cesarean section are 60% less likely to have an
adequate administration of BCG vaccine.
Discussion
Main findings
This study provides population estimates of BCG admin-
istration by two different methods in a large cohort of
children. It shows that vaccine coverage in Manhiça dis-
trict was very high for all vaccines administered in the
first year of life, surpassing the international targets for
EPI vaccine coverage. This finding is in line with results
presented from similar studies about EPI vaccine cover-
age in Mozambique [29].
This is the first vaccination coverage study in the
country using data collected by a HDSS. This prelimin-
ary information could be very relevant for future vaccine
trials and a proxy for other health interventions. It is
also important to highlight the importance of data regis-
tries in LMIC to monitor health systems’ performance,
resource allocation planning and progress in
immunization strategies. These findings call for an im-
proved system to collect information to be used for
assessing vaccine coverage, and which could hopefully
be used to compare across different countries.
In the period from 2011 to 2014, BCG coverage was
97.4%, higher than the estimation of 86.3% in Maringue
District, Sofala Province (centre Mozambique) [12] and
the nationwide 94% estimation by WHO [28]. The re-
sults of high coverage could be explained because of the
likely better health infrastructure in the district than na-
tional standards, which include two referral hospitals
plus the existence of a research centre (the CISM, which
conducts operational and translational research). The
latter, conducts at least one visit per year to each house-
hold for the purpose of HDSS work rounds of data col-
lection in the district, which could potentially affect
vaccination-seeking behaviour in the community. How-
ever, selection bias might have occurred since there is a
proportion of subjects who fail to provide a health card.
Although the main stated reason was that the caregivers
could not find the card, if those who did not find the
card had lower vaccine coverage, our estimates might
represent a slight overestimation of the true coverage.
An extra source of potential selection bias is that those
Table 1 Demographic and socioeconomic characteristics of less
than 36-months old children
Variablea n % Variable n %
Sex Mother’s antenatal visits
Boy 3979 50.4 1 to 2 170 9.8
Girl 3921 49.6 3 or more 1573 90.3
Number of
siblings
Place of delivery
None 9 0.5 Health centre 1665 95.6
1 to 2 851 48.8 Home/Way
to hospital
77 4.4
3 or above 883 50.7 Type of birth
Season of birth Natural 1655 95.0
Rainy 4329 54.8 C-Section 88 5.0
Dry 3574 45.2 Distance to health centre
Wealth Index Less than 5 km 988 19.8
1st Quintile 1312 18.4 More than 5 km 3994 80.2
2nd Quintile 1478 20.8 Mother’s marital status
3rd Quintile 1450 20.4 Single 513 10.1
4th Quintile 1451 20.4 Married/Union 3909 77.2
5th Quintile 1418 20.0 Divorced/Separated 641 12.7
Area Mother’s education
Manhiça Sede 1706 21.6 No education 2110 43.0
3 de Fevereiro 1593 20.2 Primary 2308 47.0
Ilha Josina Machel 144 1.8 Secondary or
Higher
491 10.0
Xinavane 2215 28.0 Mother’s religion
Maluana 1689 21.4 Christian 2126 44.5
Calanga 556 7.0 Muslim 42 0.9
Traditional African 2176 45.5
Others 435 9.1
a Many variables presented missing data due to lack of completeness of the
questionnaire, or because some of them were implemented in different years
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born in that period who died before the HDSS census
rounds might have had lower BCG coverage. However,
the effect of this bias, albeit unknown, could be limited,
since those with and without vaccination card had simi-
lar coverages measured by the presence of scar.
We found no statistically significant associations
with lack of BCG vaccination, except living in the
municipality of Maluana. These findings might be ex-
plained by the small number of non-vaccinated indi-
viduals (random error) or other social factors that
will require qualitative approaches in order to be
identified.
Very few BCG vaccinated children (according to their
health cards) in the district of Manhiça fail to develop
the scar. These results are comparable with findings of
scar failure in other countries, ranging from 1 to 20%
[13, 38, 39]. Potential observer bias could have taken
place, since field workers were not blind to the child
heath card information. Nonetheless, the proportion of
scar formation in children with and without health card
was similar to that of BCG vaccinated infants. If these
findings were a true overestimation, the reason behind
could be a systematic poor evaluation of the presence of
BCG scar. Conversely, the fact that many children with
Table 2 Vaccination coverage among children aged less than 36 months in the district of Manhiça (2011-2014)
Name of the
vaccine
Number of children
vaccinated (by card)
Number of children not
vaccinated (by card)
Total children evaluated
for each vaccineb
% 95% CI
BCG 7613 204 7817 97.4% (95.20, 99.59)
OPV0 7505 289 7794 96.3% (94.17, 98.54)
DPT/HepB/Hib 1 7466 311 7777 96.0% (93.83, 98.20)
OPV1 7434 338 7772 95.7% (93.52, 97.88)
DPT/HepB/Hib 2 7336 425 7761 94.5% (92.37, 96.71)
OPV2 7274 477 7751 93.8% (91.70, 96.03)
DPT/HepB/Hib 3 7195 546 7741 92.9% (90.84, 95.16)
OPV3 7126 608 7734 92.1% (90.03, 94.32)
All OPVa 7031 778 7809 90.0% (88.07, 92.30)
All DPT/HepB/Hiba 7145 640 7785 91.8% (89.72, 93.99)
Measles 6509 1093 7602 85.6% (83.55, 87.73)
BCG Bacille-Calmette Guerin, OPV Oral Polio Vaccine, DPT/HepB/Hib Diphteria Pertussis Tetanus/Hepatitis B/Haemophinlus influenzae type b
a All OPV or All DPT/HepB/Hib, refers to all doses of the vaccine having been correctly registered. It is lower than the last dose due to absence/incorrect
documentation of some of the previous doses
b Only eligible children (those who should have received a vaccine according to their age at the time of the visit and whose health card was assessed, readable
and without missing dates) were included in this column
Fig. 2 Vaccination coverage among less than 36-month old children in the district of Manhiça (2011-2014)
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Table 3 Analysis of factors associated to lack of BCG vaccination
Variable Number
of
children
lacking
BCG
according
to card
Total
number of
children
with BCG
informatio
in the card
Bivariate analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Sex
Male 101 (2.6) 3932 1.0
Female 102 (2.6) 3882 1.02 (0.77-1.35) 0.926
Number of siblings
None 0 (0) 9 –
1 to 2 11 (1.3) 844 0.67 (0.31-1.44)
3 or above 17 (1.9) 880 1.00 0.305
Season of birth
Rainy 108 (2.5) 4288 1.00
Dry 96 (2.7) 3529 1.09 (0.82-1.44) 0.578
Wealth Index
1st Quintile 42 (3.2) 1312 1.00
2nd Quintile 38 (2.6) 1478 0.82 (0.52-1.28)
3rd Quintile 41 (2.8) 1450 0.90 (0.58-1.40)
4th Quintile 28 (1.9) 1451 0.61 (0.37-0.99)
5th Quintile 38 (2.7) 1418 0.85 (0.54-1.33) 0.325
Administrative Post
Manhiça Sede 37 (2.2) 1690 1.00 1.00
3 de Fevereiro 34 (2.2) 1582 0.98 (0.61-1.57) 0.79 (0.45-1.39)
Ilha Josina Machel 1 (0.7) 144 0.31 (0.04-2.29) 0.32 (0.04-2.39)
Xinavane 57 (2.6) 2183 1.20 (0.79-1.82) 1.05 (0.59-1.89)
Maluana 65 (3.9) 1671 1.78 (1.18-2.68) 1.89 (1.18-3.00)
Calanga 10 (1.8) 547 0.83 (0.41-1.68) 0.007 0.47 (0.14-1.54) 0.003
Antenatal Visits
1 to 2 3 (1.7) 168 1.00
3 or above 25 (1.6) 1565 0.89 (0.37-2.98) 0.854
Place of delivery
Health centre 28 (1.7) 1655 1.00
Home/way to hospital 0 (0) 77 – –
Type of delivery
Natural 26 (1.6) 1645 1.00
C-Section 2 (2.3) 88 1.44 (0.34-6.2) 0.618
Mother’s marital status
Single 12 (2.4) 510 1.00 1.00
Married/Union 84 (2.2) 3868 0.92 (0.49-1.70) 0.99 (0.53-1.82)
Divorced/Separated 23 (3.6) 631 1.57 (0.77-3.19) 0.083 1.66 (0.81-3.37) 0.092
Mother’s education
No education 52 (2.5) 2089 1.00
Primary 54 (2.4) 2284 0.95 (0.64-1.39)
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no record of BCG in their card presented BCG scar
could lead to a potential underestimation of coverage es-
timates based solely on immunization card. This could
be due to bad documentation of BCG vaccination in the
immunization card (or cases where the card was lost
and replaced, and information could not be updated).
Unfortunately these potential explanations cannot be
verified.
Recent studies showing scar beneficial effects, such as
lower mortality in infants with scar [5, 11], have opened
the debate about re-vaccination [5, 40] among those fail-
ing to develop a scar. Some have suggested that scarring
could be a method to monitor vaccination performance
in resource-poor settings. On the other hand, BCG is
not recommended in HIV suspected cases and HIV-
related immunosuppression may play a role in scar re-
sponse. In a high HIV burden country such as
Mozambique, where most children are BCG vaccinated
regardless of their HIV status, we expected a lower scar
formation rate.
The timing of vaccination is very important in order
to reach the maximum protection, but also for being a
proxy of non-adherence and reduce of vaccination. [16,
17, 20, 22]. In order to measure if BCG was appropri-
ately administered, we consider a timely vaccination if it
occurred within the 28 days of life, as recommended by
WHO [19]. The results show a low proportion of de-
layed BCG vaccination (6.6%), compared to 33% found
in Tanzanian the year 2004 [15]. However, the definition
of delayed BCG vaccination differs from author to au-
thor, [19] some consider it happens only after 8 weeks
or even after 56 days [17] after birth, thus comparability
with other studies needs to be cautious. The only factor
associated with timely BCG vaccination was being deliv-
ered through a caesarean section. It is closely related
with being born in a health facility, with a skilled birth
attendant, where they will have the BCG vaccine ready
to be administered after birth.
This study had several limitations. First, selection bias
could have occured since we could only visit children
Table 3 Analysis of factors associated to lack of BCG vaccination (Continued)
Variable Number
of
children
lacking
BCG
according
to card
Total
number of
children
with BCG
informatio
in the card
Bivariate analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Secondary or higher 11 (2.3) 485 0.91 (0.47-1.75) 0.943
Mother’s religion
Christian 48 (2.3) 2104 1.00
Muslim 1 (2.5) 40 1.09 (0.15-8.16)
Traditional African 53 (2.5) 2158 1.07 (0.73-1.60) 0.902
Others 8 (1.8) 428 0.82 (0.38-1.74)
Distance to health centre
Less than 5 km 17 (1.7) 983 1.00
More than 5 km 88 (2.2) 3961 1.27 (0.75-2.15) 0.339
Fig. 3 Timeliness of BCG administration
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Table 4 Analysis of factors associated to a adequate timeliness of BCG administration (within 28 first days of life) according to
health card
Variable Timely BCG
vaccinated
(%)
Total
children
with BCG
Bivariate analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Sex
Male 3449 (93.4) 3691 1.00
Female 3399 (93.3) 3642 0.98 (0.82-1.18) 0.842
Number of siblings
None 9 (100) 9 1.00
1 to 2 750 (95.4) 786 1.25 (0.80-1.95)
3 or above 769 (94.4) 815 1.00 0.335
Season of birth
Rainy 3743 (93.3) 4012 1.00
Dry 3108 (93.5) 3324 1.03 (0.86-1.24) 0.723
Wealth Index
1st Quintile 1136 (93.3) 1218 1.00
2nd Quintile 1289 (93.5) 1378 1.05 (0.77-1.42)
3rd Quintile 1265 (93.1) 1359 0.97 (0.71-1.32)
4th Quintile 1278 (93.9) 1361 1.11 (0.81-1.52)
5th Quintile 1260 (94.3) 1336 1.19 (0.86-1.65) 0.704
Administrative Post
Manhiça Sede 1496 (94.6) 1582 1.00
3 de Fevereiro 1364 (93.0) 1466 0.77 (0.57-1.03)
Ilha Josina Machel 123 (94.6) 130 1.01 (0.46-2.23)
Xinavane 1941 (93.5) 2077 0.82 (0.62-1.08)
Maluana 1431 (91.7) 1560 0.64 (0.48-0.85)
Calanga 496 (95.2) 521 1.14 (0.72-1.80) 0.018
Antenatal Visits
1 to 2 148 (95.5) 155 1.00
3 or above 1380 (94.8) 1455 0.87 (0.39-1.92) 0.731
Place of delivery
Health centre 1458 (95.0) 1535 1.00
Home/way to hospital 69 (93.2) 74 0.73 (0.29-1.86) 0.507
Type of delivery
Natural 1453 (95.2) 1527 1.00 1.00
C-Section 75 (90.4) 83 0.48 (0.22-1.03) 0.058 0.40 (0.18-0.87) 0.021
Mother’s marital status
Single 424 (90.0) 471 1.00 1.00
Married/Union 3421 (93.8) 3649 1.66 (1.19-2.31) 1.50 (0.76-2.94)
Divorced/Separated 544 (94.4) 576 1.88 (1.18-3.00) 0.006 1.50 (0.56-4.00) 0.490
Mother’s education
No education 1836 (93.1) 1973 1.00
Primary 1994 (93.6) 2131 1.09 (0.85-1.39)
Secondary or higher 430 (74.7) 576 1.33 (0.86-2.09) 0.421
Mother’s religion
Christian 1834 (93.4) 1964 1.00
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whose adults were present at the moment of the
interview and presented the card (for evaluation of
the registration) and/or the children were present (for
scar assessment). There were 16.9% (1609/9512) of
children who did not present a health card. Although
most of them argued that adults had lost the card,
these children might live in families with more diffi-
culties in accessing the health system or not able to
have a proper follow-up of their children’s health sta-
tus, thus our vaccination coverage could be overesti-
mating the real one. Secondly, children who died
before the first round visit were not included and
might have different (potentially lower) vaccine cover-
age. Thirdly, given the discrepancies found about
BCG vaccination assessed through health card and
presence of scar, poor BCG documentation in the
card or poor evaluation of BCG scar, cannot be ruled
out. Last, due to the low number of non-vaccinated
individuals identified, the study had little power to
detect potential factors associated with absence of
vaccination.
Conclusions
This study shows high vaccination coverage in Manhiça
district; although vaccines that need several doses or that
are administered months after birth require larger efforts
to ensure all children are properly and completely vacci-
nated. The vast majority of BCG vaccines are given
within the first days after birth. Scar development occurs
in almost all infants. No associations with lack of BCG
were found, except for living in the municipality of Mal-
uana. These findings require targeted investigations to
find out potential reasons for that difference in coverage
that might benefit from tailored interventions. Prospect-
ive data collection at the time of vaccination would
avoid potential bias inherent to retrospective data collec-
tion. This research study, beyond high coverage of BCG
and other EPI vaccines, shows the importance of having
data registries in LMIC to monitor health systems’ per-
formance, resource allocation planning and progress in
immunization strategies.
Additional file
Additional file 1: Demographic and socioeconomic characteristics
of less than 36-months old children with and without card. In this
table we expand the baseline demographic and socioeconomic
characteristics of study participants depending on the availability of
the health card. (DOCX 19 kb)
Abbreviations
AIDS: Acquired immune deficiency syndrome; BCG: Bacille Calmette-Guérin;
CI: Confidence interval; CISM: Centro de Investigação em Saúde de Manhiça;
DPT/HepB/hib: Diphtheria Pertussis Tetanus/Hepatitis B/Haemophilus
influenza type b (pentavalent vaccine); DSS: Demographic surveillance
system; EPI: Expanded programme on immunization; HDSS: Health and
demographic surveillance system; HIV: Human immunodeficiency virus;
LIC: Low income Countries; LMIC: Low and middle income Countries;
OPV: Oral polio vaccine; OR: Odds ratio; TB: Tuberculosis; TST: Tuberculin skin
test; WHO: World Health Organization
Acknowledgements
This analysis is the outcome of EMC’s end of Masters’ project at MSc Clinical
Research (International Health track). The authors of this study would like to thank
all the families in the district of Manhiça. We also want to thank the staff at CISM’s
Demography department for their support in data collection. We thank the
National Tuberculosis Program staff and District Health
Authorities for their constant support. This work was been partially supported by
the Erasmus Mundus Joint Doctorate Program of the European Union through a
training grant to ALGB. ISGlobal is a member of the CERCA Programme, Generalitat
de Catalunya.
Funding
No external funding was needed for this study.
Availability of data and materials
An anonymized dataset can be made available to interested researchers after
a formal request to CISM’s Internal Scientific Committee (cci@manhica.net).
Authors’ contributions
ALGB, CS conceived the study. AN, EJ, CS, participated in data collection. JJA
and OJA participated in data management and design of forms for data
collection. EMC, AN, CS, ALGB conducted the analysis. AC provided statistical
support. EMC, EM, BS, QB, ELV, ALGB, ELV contributed to data interpretation.
ALGB, BS, EM provided direction throughout the research process. All
authors have been involved in drafting the manuscript. All authors approved
the last version as sent to the journal.
Ethics approval and consent to participate
This study was approved by the Centro de Investigação em Saúde de
Manhiça’s (CISM, from its acronym in Portuguese) Internal Scientific
Committee. Heads of households in the area under demographic
surveillance provide a written informed consent allowing to use data
collected by the HDSS for research purposes. The study was conducted
following the principles of the Declaration of Helsinki.
Table 4 Analysis of factors associated to a adequate timeliness of BCG administration (within 28 first days of life) according to
health card (Continued)
Variable Timely BCG
vaccinated
(%)
Total
children
with BCG
Bivariate analysis Multivariable analysis
OR (95%CI) p-value OR (95%CI) p-value
Muslim 35 (89.7) 39 0.62 (0.22-1.77)
Traditional African 1907 (94.2) 2025 1.15 (0.89-1.48)
Others 376 (93.3) 403 0.99 (0.64-1.52) 0.528
Distance to health centre
Less than 5 km 61 (72.6) 84 1.00 1.00
More than 5 km 205 (5.9) 3495 1.24 (0.92-1.66) 0.161 1.48 (0.90-2.44) 0.118
Marbán-Castro et al. BMC Pediatrics  (2018) 18:56 Page 10 of 12
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1ISGlobal, Barcelona Ctr. Int. Health Res. (CRESIB), Hospital Clínic-Universitat
de Barcelona, C/Rosselló 132, 08036 Barcelona, Spain. 2Centro de
Investigação em Saúde da Manhiça (CISM), Rua 12, Vila de Manhiça, CP 1929
Maputo, Mozambique. 3ICREA, Pg. Lluís Companys 23, 08010 Barcelona,
Spain. 4Amsterdam Institute for Global Health and Development (AIGHD),
Amsterdam, The Netherlands.
Received: 31 March 2017 Accepted: 23 January 2018
References
1. WHO. Global Tuberculosis Report 2015 [Available from: http://apps.who.int/
iris/bitstream/10665/191102/1/9789241565059_eng.pdf.
2. Roth A, Garly ML, Jensen H, Nielsen J, Aaby P. Bacillus Calmette-Guerin
vaccination and infant mortality. Exp Rev Vaccines. 2006;5(2):277–93.
3. Montagnani C, Chiappini E, Galli L, de Martino M. Vaccine against
tuberculosis: what’s new? BMC Infect Dis. 2014;14(Suppl 1):S2.
4. Van-Dunem JC, Rodrigues LC, Alencar LC, Militao-Albuquerque Mde F, Ximenes
RA. Effectiveness of the first dose of BCG against tuberculosis among HIV-infected,
predominantly immunodeficient children. Biomed Res Int. 2015;2015:275029.
5. Dhanawade SS, Kumbhar SG, Gore AD, Patil VN. Scar formation and
tuberculin conversion following BCG vaccination in infants: a prospective
cohort study. J Family Med Prim Care. 2015;4(3):384–7.
6. Abubakar I, Pimpin L, Ariti C, Beynon R, Mangtani P, Sterne JA, et al.
Systematic review and meta-analysis of the current evidence on the
duration of protection by bacillus Calmette-Guerin vaccination against
tuberculosis. Health Technol Assess. 2013;17(37):1–372. v-vi
7. Roy A, Eisenhut M, Harris RJ, Rodrigues LC, Sridhar S, Habermann S, et al.
Effect of BCG vaccination against mycobacterium tuberculosis infection in
children: systematic review and meta-analysis. BMJ (Clinical research ed).
2014;349:g4643.
8. WHO. Systematic review of the non-specific effects of BCG, DTP and
measles containing vaccines. 2014. [Available from: http://www.who.int/
immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_
Report_to_SAGE_14_Mar_FINAL.pdf ].
9. Nguipdop-Djomo P, Heldal E, Rodrigues LC, Abubakar I, Mangtani P.
Duration of BCG protection against tuberculosis and change in
effectiveness with time since vaccination in Norway: a retrospective
population-based cohort study. Lancet Infect Dis. 2016;16(2):219–26.
10. Storgaard L, Rodrigues A, Martins C, Nielsen BU, Ravn H, Benn CS, et al.
Development of BCG scar and subsequent morbidity and mortality in rural
Guinea-Bissau. Clin Infect Dis. 2015;61(6):950–9.
11. Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, et al.
BCG vaccination scar associated with better childhood survival in
Guinea-Bissau. Int J Epidemiol. 2005;34(3):540–7.
12. Consonni D, Montenegro Agorostos Karagianis MM, Bufardeci G.
Immunisation with BCG in the Maringue District, Sofala Province,
Mozambique. Tuberc Res Treat. 2013;2013:312065.
13. Pang Y, Kang W, Zhao A, Liu G, Du W, Xu M, et al. The effect of
bacille Calmette-Guerin vaccination at birth on immune response in
China. Vaccine. 2015;33(1):209–13.
14. Animaw W, Taye W, Merdekios B, Tilahun M, Ayele G. Expanded
program of immunization coverage and associated factors among
children age 12-23 months in Arba Minch town and Zuria District,
southern Ethiopia, 2013. BMC Public Health. 2014;14:464.
15. Le Polain de Waroux O, Schellenberg JR, Manzi F, Mrisho M, Shirima K,
Mshinda H, et al. Timeliness and completeness of vaccination and risk
factors for low and late vaccine uptake in young children living in
rural southern Tanzania. Int Health. 2013;5(2):139–47.
16. Scott S, Odutola A, Mackenzie G, Fulford T, Afolabi MO, Lowe Jallow Y,
et al. Coverage and timing of children’s vaccination: an evaluation of
the expanded programme on immunisation in the Gambia. PLoS One.
2014;9(9):e107280.
17. Fadnes LT, Jackson D, Engebretsen IM, Zembe W, Sanders D, Sommerfelt H,
et al. Vaccination coverage and timeliness in three south African areas: a
prospective study. BMC Public Health. 2011;11:404.
18. Canavan ME, Sipsma HL, Kassie GM, Bradley EH. Correlates of complete
childhood vaccination in east African countries. PLoS One. 2014;9(4):e95709.
19. Schoeps A, Ouedraogo N, Kagone M, Sie A, Muller O, Becher H. Socio-
demographic determinants of timely adherence to BCG, Penta3,
measles, and complete vaccination schedule in Burkina Faso. Vaccine.
2013;32(1):96–102.
20. Gram L, Soremekun S, ten Asbroek A, Manu A, O'Leary M, Hill Z, et al. Socio-
economic determinants and inequities in coverage and timeliness of early
childhood immunisation in rural Ghana. Tropical Med Int Health. 2014;19(7):802–11.
21. Gidado S, Nguku P, Biya O, Waziri NE, Mohammed A, Nsubuga P, et al.
Determinants of routine immunization coverage in Bungudu, Zamfara state,
northern Nigeria, may 2010. Pan Afr Med J. 2014;18(Suppl 1):9.
22. Thysen SM, Byberg S, Pedersen M, Rodrigues A, Ravn H, Martins C, et
al. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an
observational study. BMC Public Health. 2014;14:1037.
23. Odusanya OO, Alufohai EF, Meurice FP, Ahonkhai VI. Determinants of
vaccination coverage in rural Nigeria. BMC Public Health. 2008;8:381.
24. Thorpe S, VanderEnde K, Peters C, Bardin L, Yount KM. The influence of
Women’s empowerment on child immunization coverage in low, lower-
middle, and upper-middle income countries: a systematic review of the
literature. Matern Child Health J. 2016;20(1):172–86.
25. Garcia-Basteiro AL, Lopez-Varela E, Respeito D, Gonzalez R, Naniche D,
Manhica I, et al. High tuberculosis burden among people living with
HIV in southern Mozambique. Eur Respir J. 2015;45(2):547–9.
26. Garcia-Basteiro AL, Respeito D, Augusto OJ, Lopez-Varela E, Sacoor C,
Sequera VG, et al. Poor tuberculosis treatment outcomes in southern
Mozambique (2011-2012). BMC Infect Dis. 2016;16:214.
27. Ministry of Health, Republic of Mozambique. National Immunization Plan.
Comprehensive Multi-Year Plan (cMYP) 2012-2016. Available at http://www.
nationalplanningcycles.org/sites/default/files/planning_cycle_repository/
mozambique/mozambique_cmyp_2012-2016_.pdf.
28. WHO. The Global Summary Monitoring System for Vaccine Preventable
Diseases. 2016. [Available from: http://apps.who.int/immunization_
monitoring/globalsummary ].
29. Lanaspa M, Balcells R, Sacoor C, Nhama A, Aponte JJ, Bassat Q. The
performance of the expanded programme on immunization in a rural area
of Mozambique. Acta Trop. 2015;149:262–6.
30. Marais BJ, Seddon JA, Detjen AK, van der Werf MJ, Grzemska M, Hesseling
AC, et al. Interrupted BCG vaccination is a major threat to global child
health. Lancet Respir Med. 2016;4(4):251–3.
31. Sacoor C, Nhacolo A, Nhalungo D, Aponte JJ, Bassat Q, Augusto O, et al.
Profile: Manhica health research centre (Manhica HDSS). Int J Epidemiol.
2013;42(5):1309–18.
32. Gonzalez R, Munguambe K, Aponte J, Bavo C, Nhalungo D, Macete E, et al.
High HIV prevalence in a southern semi-rural area of Mozambique: a
community-based survey. HIV medicine. 2012;13(10):581–8.
33 García-Basteiro AL, Miranda Ribeiro R, Brew J, Sacoor C, Valencia S, Bulo H,
Cobelens F, Macete E. Tuberculosis on the rise in southern Mozambique
(1997-2012). Eur Respir J. 2017;49(3).
34. Timaeus I, Garaham W. Measuring adult mortality in developing countries: a
review and assessment of methods. Population, Health, and Nutridon
Division, Population and Human Resources Department. World Bank; 1988.
Available at: http://documents.worldbank.org/curated/en/
386261468765039030/pdf/multi0page.pdf.
35. Lopez-Varela E, Augusto OJ, Guerra L, Respeito D, Sacoor C, Sacarlal J, et al.
Low paediatric tuberculosis case detection rate in southern Mozambique.
Eur Respir J. 2016;47(3):1003–5.
36. Lopez-Varela E, Augusto OJ, Gondo K, Garcia-Basteiro AL, Fraile O, Ira T, et al.
Incidence of tuberculosis among young children in rural Mozambique.
Pediatr Infect Dis J. 2015;34(7):686–92.
37. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how
to use principal components analysis. Health Policy Plan. 2006;21(6):459–68.
38. A Prospective Study of Bacillus Calmette-Guérin Scar Formation and Tuberculin
Skin Test Reactivity in Infants in Lima, Peru. Pediatrics. 2003;112(4):e298.
Marbán-Castro et al. BMC Pediatrics  (2018) 18:56 Page 11 of 12
39. Santiago EM, Lawson E, Gillenwater K, Kalangi S, Lescano AG, Du Quella
G, et al. A prospective study of bacillus Calmette-Guerin scar formation
and tuberculin skin test reactivity in infants in lima. Peru Pediatrics.
2003;112(4):e298.
40. Timmermann CA, Biering-Sorensen S, Aaby P, Fisker AB, Monteiro I,
Rodrigues A, et al. Tuberculin reaction and BCG scar: association with infant
mortality. Tropical Med Int Health. 2015;20(12):1733–44.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Marbán-Castro et al. BMC Pediatrics  (2018) 18:56 Page 12 of 12
